ALT240628P7000
- 0.50
- -0.10-16.67%
Altimmune Newsroom
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Express News | Shares of Altimmune Are Trading Higher After a NYPost Article Highlighted a Study Comparing the Company's Pemvidutide to Ozempic
Express News | Watching Altimmune; Traders Circulate New Yor Post Article 'New Weight Loss Drug May Be Better Than Ozempic — Here's How'
Why Are Altimmune Shares Trading Lower Wednesday?
Altimmune, Inc. (NASDAQ:ALT) shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's chief financial officer. What To Know: Eisenstadt'
Altimmune Drops 15% After Sudden Death of Finance Chief
By Victor Swezey Shares of Altimmune fell Wednesday after Chief Financial Officer Richard Eisenstadt died suddenly. In afternoon trading, the stock was down 15% to $6.31. Shares are still up 83% in
Express News | Altimmune Shares Are Trading Lower Following the Passing of CEO Richard Eisenstadt
Express News | Altimmune Shares Down 9% at $6.7 After Co Announces Passing of CFO
Altimmune Initiates Search For New CFO - Quick Facts
Express News | Altimmune Inc: On June 25, Appointed Andrew Shutterly as Acting Chief Financial Officer
Express News | Altimmune Announces Passing Of Chief Financial Officer, Richard Eisenstadt; Eisenstadt's Duties Are Being Assumed And Performed Bt Finance And Accounting Team Until Replacement Is Named
Express News | Altimmune Inc: Eisenstadt's Duties Are Being Performed by Finance and Accounting Team
Express News | Altimmune Inc: CFO Richard Eisenstadt Passed Away Unexpectedly on Monday
Press Release: Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt
Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt GAITHERSBURG, Md., June 26, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company,
Pfizer's CEO announced the development of three new weight loss drugs, one of which is not a GLP-1 medication.
Pfizer's (PFE.US) CEO, Albert Bourla, said that the pharmaceutical company is testing three new weight loss drugs.
B.Riley Financial Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20
B.Riley Financial analyst Mayank Mamtani maintains $Altimmune(ALT.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 27.9% and
Crypto Under Pressure, Good Buy or Goodbye: Market Domination
Altimmune Reports Positive Results in Weight-loss Drug Trial
Tandem Diabetes, DexCom See Weakness Following ADA Conference
ADA 2024: Altimmune's GLP-1 Drug Shows Weight Loss Potential